Purpose: Targeted therapy is the cornerstone of treatment of advanced -mutant non-small-cell lung cancer (NSCLC). Next-generation sequencing (NGS), the preferred method for genotyping, typically requires several weeks. Here, we assessed workflows designed to rapidly identify patients with actionable mutations and reduce time to initiation (TTI) of epidermal growth factor receptor (EGFR)-directed therapy.
Patients And Methods: We performed rapid testing for L858R mutations and exon 19 deletions on paraffin-embedded or frozen section biopsy specimens from newly diagnosed patients with metastatic NSCLC by using an -specific assay (rapid test). To determine clinical utility, we assessed concordance with NGS results, turnaround time, and TTI of EGFR therapy, and we evaluated reimbursement data.
Results: Between January 2015 and September 2017, we performed 243 rapid tests and identified mutations in 43 patients (18%). With NGS results as a reference, sensitivity and specificity of the rapid polymerase chain reaction assay were 98% and 100%, respectively. The median turnaround time for NGS was 14 days, compared with 7 days for rapid testing ( < .001). In the rapid group, 95% of patients received an EGFR inhibitor in the first-line setting. The median TTI of EGFR therapy was significantly shorter in the rapid cohort when compared with 121 historical cases (22 37 days; = .01). Escalation of the initiative into an interdisciplinary ultra-rapid next-day frozen-section workflow for highly symptomatic patients (n = 8) resulted in a reduction in the median (± standard deviation) turnaround time to 1 ± 0.4 days and allowed several patients to initiate therapy within 1 week of biopsy. An extended 9-month clinical evaluation phase confirmed operational sustainability (turnaround times: ultra-rapid, 0.81 ± 0.4 days; rapid, 3 ± 1.5 days), and a 63% reimbursement rate indicated financial sustainability.
Conclusion: Rapid genotyping facilitates earlier initiation of EGFR-directed therapies without compromising NGS workflows.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200882 | PMC |
| http://dx.doi.org/10.1200/PO.17.00299 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Out-of-distribution generalization for segmentation of lymph node metastasis in breast cancer.
Sci Rep
January 2025
Department of Electrical, Computer, and Biomedical Engineering, Toronto Metropolitan University, Toronto, ON, Canada.
Pathology provides the definitive diagnosis, and Artificial Intelligence (AI) tools are poised to improve accuracy, inter-rater agreement, and turn-around time (TAT) of pathologists, leading to improved quality of care. A high value clinical application is the grading of Lymph Node Metastasis (LNM) which is used for breast cancer staging and guides treatment decisions. A challenge of implementing AI tools widely for LNM classification is domain shift, where Out-of-Distribution (OOD) data has a different distribution than the In-Distribution (ID) data used to train the model, resulting in a drop in performance in OOD data.
View Article and Find Full Text PDFEvaluation of a Point-of-Care-Viscoelastic Coagulation Device in Hispaniolan Amazon Parrots ().
J Avian Med Surg
January 2025
Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Viscoelastic testing evaluates the formation and lysis of a clot over time, allowing more complete assessment of patient hemostasis in real time, whereas traditional tests, such as prothrombin time and partial thromboplastin time, only measure coagulation factor function. Patient-side viscoelastic coagulation monitors are easy to use, portable, and provide faster turnaround time than commercial laboratories. Viscoelastic testing requires only 0.
View Article and Find Full Text PDFRapid Detection of Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling.
Biomolecules
December 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Acute promyelocytic leukemia (APL) accounts for approximately 10-15% of newly diagnosed acute myeloid leukemia cases and presents with coagulopathy and bleeding. Prompt diagnosis and treatment are required to minimize early mortality in APL as initiation of all-trans retinoic acid therapy rapidly reverses coagulopathy. The fusion is a hallmark of APL and its rapid identification is essential for rapid initiation of specific treatment to prevent early deaths from coagulopathy and bleeding and optimize patient outcomes.
View Article and Find Full Text PDFValidation of glucose and lactate in cerebrospinal fluid (CSF) on a Radiometer blood gas analyzer ABL90 Flex plus.
Clin Biochem
January 2025
Pathology and Laboratory Medicine Program, Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada; Memorial University of Newfoundland, Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada. Electronic address:
Purpose: Rapid determination of cerebrospinal fluid (CSF) glucose and lactate is required by emergency rooms and intensive care units. Long turnaround time (TAT) on test results negatively impacts timely diagnosis and treatment of neurological infections like meningitis.
Methods: The CSF glucose and lactate assays were evaluated on a blood gas analyzer, Radiometer ABL90 Flex Plus.
Pathogen sequencing is an important tool for disease surveillance and demonstrated its high value during the COVID-19 pandemic. Viral sequencing during the pandemic allowed us to track disease spread, quickly identify new variants, and guide the development of vaccines. Tiled amplicon sequencing, in which a panel of primers is used for multiplex amplification of fragments across an entire genome, was the cornerstone of SARS-CoV-2 sequencing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!